Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)

US — Healthcare Sector
Peers: BWSN  BWNB  RILYT  RILYO  SPNT-PB 

Automate Your Wheel Strategy on HROWL

With Tiblio's Option Bot, you can configure your own wheel strategy including HROWL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HROWL
  • Rev/Share 5.9414
  • Book/Share 1.5658
  • PB 19.0267
  • Debt/Equity 4.0744
  • CurrentRatio 0.9067
  • ROIC 0.0159

 

  • MktCap 1100254008.0
  • FreeCF/Share -1.0218
  • PFCF -30.055
  • PE -49.5058
  • Debt/Assets 0.6316
  • DivYield 0
  • ROE -0.3577

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)

  • IPO Date 2021-05-07
  • Website http://www.harrowinc.com
  • Industry Medical - Pharmaceuticals
  • CEO Mark L. Baum
  • Employees 217
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.